Loading clinical trials...

Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01208779

Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific da...

Lead sponsor: AstraZeneca•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

Not Yet RecruitingPhase 2

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

NCT07195227 · Hormon Receptor Positive Breast Cancer, Breast Cancer

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 17, 2013Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment90

Start dateJan 2011

Last updatedJul 17, 2013

Condition

Hormon Receptor Positive Breast Cancer

Locations shown

Research Site

Vojvodina, Sremska Kamenica

Research Site

Belgrade

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 17, 2013Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions